60 Degrees Pharmaceuticals receives additional U.S. patent covering tafenoquine

60 Degrees Pharmaceuticals announced that the United States Patent and Trademark Office, USPTO, has awarded 60P a patent covering the use of tafenoquine for prevention of Plasmodium falciparum malaria. Tafenoquine is the active molecule in ARAKODA, the Company’s FDA-approved drug for malaria prevention in individuals aged 18 years and older for up to six months of continuous dosing. “Securing this patent is important for 60P,” said Chief Executive Officer, Geoff Dow. “It ensures that 60P can continue to maintain a long-term competitive position for the regimen of tafenoquine known as ARAKODA in the U.S. marketplace. Tafenoquine is effective against all species and stages of malaria. Furthermore, physicians can administer it weekly during travel. The current market leading malaria drugs do not kill latent vivax liver stages and must be given daily. We are pleased to have secured this additional patent on tafenoquine.”